Background A proportion of patients with an implantable cardioverter‐defibrillator (ICD) in
prevention of sudden cardiac death will only receive their first appropriate ICD therapy (AT) …

Objective To estimate the baseline risk of arrhythmic death required for prophylactic
implantable cardiac defibrillators (ICDs) to result in clinically meaningful survival benefits in …

Implantable cardioverter defibrillators (ICDs) significantly contribute to the prevention of
sudden cardiac death in selected patients. However, it is essential to identify those who are …

Background Registry data add important information to randomized controlled trials (RCT)
on real‐life aspects of implantable cardioverter‐defibrillator (ICD) patients with and without …

BACKGROUND: Patients with advanced heart disease are at risk from sudden death;
however, benefit from implantable cardioverter defibrillators (ICDs) may be limited as a …

Objective: To investigate the effect of implantable cardioverter defibrillator (ICD) on primary
prevention of sudden cardiac death (SCD) in patients with high risk. Methods: This …

Aims Incidence of implantable cardioverter-defibrillator (ICD) therapy in secondary
prevention has been assessed in randomized trials and registries. However, results are …

Introduction Cardiac resynchronization defibrillator (CRT‐D) as primary prevention is known
to reduce mortality. At the time of replacement, higher age and comorbidities may attenuate …

Objectives: Our purpose was to demonstrate that strategically chosen implantable
cardioverter-defibrillator (ICD) ventricular tachycardia (VT) or ventricular fibrillation (VF) …

Aims Much controversy exists concerning the efficacy of primary prophylactic implantable
cardioverter-defibrillators (ICDs) in patients with low ejection fraction due to coronary artery …